Masahiro Ishikane Selected Research

Masahiro Ishikane Research Topics

Disease

27	COVID-19 02/2024 - 06/2020
11	Infections 12/2023 - 01/2014
8	Pneumonia (Pneumonitis) 01/2023 - 06/2020
3	Human Influenza (Influenza) 01/2023 - 11/2016
3	Sepsis (Septicemia) 12/2022 - 01/2019
3	COVID-19 reinfection 11/2022 - 07/2021
3	Bacteremia 11/2022 - 01/2017
2	Hemorrhage 02/2024 - 08/2022
2	Communicable Diseases (Infectious Diseases) 10/2023 - 02/2020
2	Diarrhea 01/2023 - 01/2022
2	Reinfection 11/2022 - 07/2021
2	Respiratory Insufficiency (Respiratory Failure) 11/2022 - 01/2022
2	Fever (Fevers) 10/2022 - 07/2022
2	Thrombosis (Thrombus) 08/2022 - 11/2021
2	Critical Illness (Critically Ill) 01/2021 - 08/2020
2	Candidemia 01/2019 - 01/2016
1	Tuberculosis (Tuberculoses) 03/2023
1	Pneumococcal Meningitis (Streptococcus pneumoniae Meningitis) 03/2023
1	Mpox (monkeypox) 02/2023
1	Nausea 02/2023
1	Liver Diseases (Liver Disease) 01/2023
1	Rheumatoid Arthritis 01/2023
1	Common Cold 01/2023
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2023
1	Bacterial Infections (Bacterial Infection) 10/2022
1	Marginal Zone B-Cell Lymphoma (MALT Lymphoma) 08/2022
1	Hematologic Neoplasms (Hematological Malignancy) 08/2022
1	Disease Progression 07/2022
1	Breakthrough Infections 07/2022
1	Aphasia (Dysphasia) 05/2022
1	Hemiplegia (Spastic Hemiplegia) 05/2022
1	Abscess 05/2022
1	Clostridium Infections 02/2022
1	Meningitis 12/2021
1	Obesity 11/2021
1	Hypertension (High Blood Pressure) 11/2021

Drug/Important Bio-Agent (IBA)

8	Anti-Bacterial Agents (Antibiotics)IBA 10/2022 - 01/2017
6	VaccinesIBA 08/2022 - 11/2016
5	Immunoglobulin G (IgG)IBA 12/2023 - 07/2021
3	Heparin (Liquaemin)FDA LinkGeneric 02/2024 - 06/2020
3	CytokinesIBA 01/2023 - 08/2020
3	Neutralizing AntibodiesIBA 11/2022 - 07/2021
3	RNA (Ribonucleic Acid)IBA 08/2022 - 11/2020
2	Viral RNAIBA 12/2023 - 01/2022
2	Oxygen (Dioxygen)IBA 03/2023 - 07/2021
2	Fatty Acid-Binding ProteinsIBA 03/2023 - 08/2020
2	fibrin fragment D (D-dimer)IBA 01/2023 - 11/2021
2	AntibodiesIBA 11/2022 - 07/2021
2	Proteins (Proteins, Gene)FDA Link 06/2022 - 07/2021
2	AnticoagulantsIBA 11/2021 - 10/2021
2	FluoroquinolonesIBA 01/2021 - 01/2021
1	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 02/2024
1	Immunoglobulin A (IgA)IBA 12/2023
1	Secretory Immunoglobulin A (SIgA)IBA 12/2023
1	acceleratory factor from growth hormone (AcG)IBA 10/2023
1	3- (2- methoxyphenyl)- 5- methoxy- 1,3,4- oxadiazol- 2(3H)- oneIBA 10/2023
1	AntigensIBA 03/2023
1	brincidofovirIBA 02/2023
1	tecovirimatIBA 02/2023
1	Alanine Transaminase (SGPT)IBA 02/2023
1	Cidofovir (Vistide)FDA Link 02/2023
1	Antiviral Agents (Antivirals)IBA 02/2023
1	COVID-19 VaccinesIBA 01/2023
1	Branched-Chain Amino AcidsIBA 01/2023
1	PutrescineIBA 01/2023
1	SpermidineIBA 01/2023
1	Inactivated VaccinesIBA 01/2023
1	MacrolidesIBA 01/2023
1	Vitamin B 6IBA 01/2023
1	Proton Pump InhibitorsIBA 01/2023
1	AerosolsIBA 12/2022
1	arbekacinIBA 09/2022
1	Bendamustine Hydrochloride FDA Link 08/2022
1	Rituximab (Mabthera)FDA Link 08/2022
1	2019-nCoV Vaccine mRNA-1273IBA 06/2022
1	Acyclovir (Aciclovir)FDA LinkGeneric 03/2022
1	Ivermectin (Mectizan)FDA Link 01/2022
1	Messenger RNA (mRNA)IBA 12/2021
1	BNT162 VaccineIBA 12/2021
1	Explosive Agents (Explosives)IBA 09/2021
1	Polystyrenes (Polystyrene)IBA 06/2021
1	Polymyxin B (Aerosporin)FDA LinkGeneric 06/2021
1	Therapeutic UsesIBA 06/2021
1	Influenza Vaccines (Influenza Vaccine)FDA Link 05/2021
1	ChemokinesIBA 01/2021
1	Interleukin-6 (Interleukin 6)IBA 01/2021
1	Third Generation CephalosporinsIBA 01/2021

Therapy/Procedure

8	Therapeutics 02/2023 - 01/2014
2	Renal Dialysis (Hemodialysis) 11/2022 - 11/2020
2	Length of Stay 11/2022 - 01/2016
2	Ambulatory Care (Outpatient Care) 05/2021 - 02/2020
1	Synovectomy 03/2023
1	Oral Administration 02/2023
1	Tracheostomy 12/2022
1	Catheters 12/2022
1	Transjugular Intrahepatic Portasystemic Shunt 12/2022
1	Nebulizers and Vaporizers (Inhaler) 12/2022
1	Critical Care (Surgical Intensive Care) 11/2022
1	Cannula 07/2021
1	Hemoperfusion 06/2021